Hypertension Notification Feature (HTNF)

Cardiology Internal Medicine Nephrology

Integrated into apple watch and watchos
Regulatory Status Disclosed

Overview

The Hypertension Notification Feature (HTNF) is a software-only mobile medical application integrated into the Apple Watch and iPhone’s Health app. It analyzes photoplethysmography (PPG) data opportunistically collected by the Apple Watch’s optical heart sensor over 30-day periods to identify patterns suggestive of hypertension. Upon detecting such patterns, the feature provides a ‘Possible Hypertension’ notification to the user on their Apple Watch and paired iPhone. It is intended for over-the-counter (OTC) use by adults aged 22 and over who have not been previously diagnosed with hypertension and is not for use during pregnancy. The HTNF is designed as a screening tool to encourage users to consult a healthcare professional and to initiate home blood pressure monitoring with a traditional cuff, rather than providing a diagnosis or direct blood pressure measurements.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Passive monitoring of blood vessel responses using optical heart sensor data.
  • Advanced algorithm analyzes 30-day data windows for patterns consistent with chronic hypertension.
  • Provides 'Possible Hypertension' notifications on Apple Watch and paired iPhone.
  • Prompts users to conduct 7-day home blood pressure monitoring with an upper-arm cuff.
  • Enables logging of blood pressure measurements directly within the Apple Health app.
  • Offers blood pressure classifications based on established guidelines from the American Heart Association (AHA) and European Society of Cardiology (ESC).
  • Supports data export (e.g., PDF) of logged blood pressure measurements for sharing with healthcare providers.
  • Not intended for diagnosis or treatment, but as an early warning and screening tool.

Use Cases

  • Early detection and screening for previously undiagnosed hypertension in adults.
  • Encouraging users to adopt regular home blood pressure monitoring practices.
  • Facilitating informed discussions between patients and healthcare professionals regarding hypertension risk and next steps.
  • Supporting earlier intervention and more informed treatment decisions by clinicians.
  • Remote monitoring of hypertension risk by individuals.

What Physicians Need to Know

Hypertension Detection
The Hypertension Notification Feature (HTNF) analyzes data collected by the optical heart sensor over 30-day periods to detect patterns suggestive of hypertension.
Real-Time Alert Capability
Users receive a notification if patterns consistent with hypertension are detected after a 30-day evaluation period. This is not an immediate alert for a single high reading.
Target User Group
The feature is intended for individuals aged 22 years or older who have not been previously diagnosed with hypertension and are not pregnant.
AHA/ACC Guideline Alignment
Upon receiving a notification, users are prompted to log their blood pressure for seven days using a third-party blood pressure cuff and discuss the results with their healthcare provider, aligning with American Heart Association (AHA) guidelines for diagnosis and management. The Health app's blood pressure logging feature includes classifications based on AHA and European Society of Cardiology (ESC) guidelines.
Cardiac Monitoring Integration
The HTNF integrates with the Apple Health app for logging and reviewing blood pressure data. It prompts users to utilize compatible third-party, cuff-based blood pressure monitors for actual measurements, which can then sync data to the Health app.
Physician Tip

Physicians should advise patients that the Hypertension Notification Feature (HTNF) is a screening tool for possible hypertension, not a diagnostic device. A notification from HTNF warrants follow-up with a validated, cuff-based blood pressure measurement and a medical consultation for proper diagnosis and management. It is crucial to emphasize that this feature is not intended for individuals already diagnosed with hypertension, those under 22 years old, or pregnant individuals. Patients should also be aware that the Apple Watch cannot detect heart attacks or other acute cardiac conditions, and any concerning symptoms should prompt immediate medical attention.

The Hypertension Notification Feature itself integrates seamlessly with the Apple Health app, where users can view their notification history and manage related health data. For accurate blood pressure readings, the feature relies on integration with compatible third-party, cuff-based blood pressure monitors that can wirelessly sync measurements directly into the Apple Health app, providing a comprehensive log for review by healthcare providers.

Details

Category Cardiology AI, Patient Engagement & Education, Wearables & Remote Monitoring (RPM)
Pricing Integrated into apple watch and watchos
  • The Hypertension Notification Feature is an integrated software feature of compatible Apple Watch models (Series 9 and later, Ultra 2 and later) running watchOS 26, and is not a separately priced product or subscription
DeploymentIntegrated into Apple Watch (Series 9 and later, Ultra 2 and later) and iPhone (via Health app) running watchOS 26.
Compliance
BAA AvailableUnknown AI-estimated
HIPAA Compliant No AI-estimated
FDA Status 1 AI-estimated

The Hypertension Notification Feature (HTNF) received FDA clearance (K250507) on September 11, 2025, as a Class II medical device under the product code QXO, categorized as 'Cardiovascular Machine Learning-Based Notification Software'. It is cleared as a screening tool to identify patterns suggestive of hypertension, not for diagnosis, treatment, or direct blood pressure measurement.

Integrations
EHR Not specified
Specialties Cardiology, Internal Medicine, Nephrology

What the Web Says

The Apple Watch Hypertension Notification Feature (HTNF) uses photoplethysmography signals to notify users of possible hypertension without a blood pressure cuff, prompting further evaluation. It is not intended to diagnose hypertension but rather to act as a screening tool. The feature analyzes data over a 30-day period to detect consistent patterns that may indicate chronic high blood pressure.

Overall: Mixed

Strengths

  • Increases awareness of potential hypertension, a 'silent killer' that often goes undiagnosed.
  • Can prompt users to seek clinical evaluation and engage with the healthcare system for early detection and treatment.
  • Utilizes advanced machine learning and optical heart sensors for passive, background monitoring.
  • FDA cleared, lending a sense of accuracy and safety.
  • Available on several Apple Watch models (Series 9, 10, 11, Ultra 2, Ultra 3) with watchOS 26, making it accessible to many existing users.
  • Can help reduce clinical inertia by encouraging proactive health management.

Limitations

  • Low sensitivity (41.2% overall), meaning a significant percentage of individuals with undiagnosed hypertension may not receive an alert.
  • Risk of false reassurance if no alert is received, potentially discouraging individuals from seeking appropriate screening.
  • Does not provide actual blood pressure readings (mmHg), only notifications of possible hypertension.
  • Performance can vary by age, race, and ethnicity, with lower sensitivity in some subgroups.
  • Requires 30 days of continuous data before notifications can begin.
  • Not a substitute for traditional, cuff-based blood pressure measurements and diagnosis.

Based on reviews from: JAMA, Reddit (r/apple, r/AppleWatch, r/gadgets), American Heart Association Journals, HCPLive, MedTech Dive, Apple (Hypertension Notifications Validation Paper), University of Utah Health, The BMJ, Hospital da Luz, How-To Geek, Gizmochina, Bilal Tech25, Computerworld, Notebookcheck News

Last updated: 2026-07-17

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Hypertension Notification Feature (HTNF)

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

HLTH
Apple Receives FDA Nod For Hypertension Notification Feature
Apple received FDA clearance for its Hypertension Notification Feature on select smartwatches, which uses an algorithm to analyze optical heart sensor data for signs of hypertension. The feature is expected to alert over one million people to possible undiagnosed high blood pressure within the first year and will be available on Apple Watch Series 9, 10, 11, Ultra 2, and Ultra 3 models running watchOS 26.
2025-09
Mashable
Apple gets the FDA green light for Hypertension Notification feature
Apple announced that its Hypertension Notification feature has been cleared by the FDA and will be available in over 150 countries and regions. The feature, which uses an optical sensor and machine learning to monitor for signs of hypertension, will be accessible with watchOS 26 on Apple Watch Series 9 or later, as well as Apple Watch Ultra 2 and later.
2025-09
JAMA (Journal of the American Medical Association)
Impact of the Apple Watch Hypertension Notification Feature for Population Screening
This article discusses the Apple Watch Hypertension Notification Feature, cleared by the FDA in September 2025, which uses photoplethysmography signals to notify users of possible hypertension without a blood pressure cuff. While it offers new opportunities for identifying undiagnosed hypertension, the feature's validation study showed that 41.2% of individuals with undiagnosed hypertension received an alert, while 58.8% did not, raising concerns about potential misclassification and false reassurance.
2025-09
Apple
Hypertension Notifications Validation Paper
This paper details the development and validation of the Apple Watch Hypertension Notification Feature, which analyzes PPG data over 30-day intervals to detect signs of hypertension in users aged 22 or older who have not been previously diagnosed. The feature, cleared by the FDA, does not directly measure blood pressure but aims to alert users to possible hypertension, prompting further evaluation.
2025-09
American Heart Association Journals
Apple Watch for Hypertension Screening
The Apple Watch's Hypertension Notification Feature, cleared by the FDA, represents a significant development in digital health, but concerns remain regarding its low sensitivity and potential for misclassification. The article highlights that the feature does not measure blood pressure directly and that regulatory clearance does not guarantee validation using international protocols, emphasizing the need for rigorous evaluation and a standardized framework for such technologies.
2026-01
MedTech Dive
Apple Watch's hypertension feature may miss some cases, researchers find
A research letter in JAMA indicates that the Apple Watch's hypertension notification feature may miss cases across different demographics, with Apple's validation study showing that about 41% of people with undiagnosed hypertension received an alert, while nearly 59% did not. Researchers caution that false reassurance could lead to missed opportunities for early detection and treatment, stressing the need for rigorous validation and improved accuracy for cuffless devices.
2026-02
The BMJ
Apple smartwatch hypertension feature risks false reassurance, warn doctors
Doctors warn that Apple Watch's hypertension notification feature, which uses a light sensor to detect blood volume changes, carries risks of false reassurance and increased workload for clinical services. The feature is not intended to diagnose hypertension, and its reported sensitivities and specificities are modest, potentially leading to unnecessary follow-up measurements or delayed diagnosis.
2026-02
How-To Geek
Smartwatch Hypertension Notifications: How Seriously Should You Take It?
The Apple smartwatch hypertension notification feature, approved by the FDA in September 2025, is designed to alert users to possible hypertension and prompt further evaluation, but it does not provide blood pressure readings. While it can be useful, Apple's own validation study showed that 58.8% of people with undiagnosed hypertension did not receive an alert, and guidelines do not recommend wearables for diagnosing and managing high blood pressure.
2026-05

Videos

Product demos, reviews, and walkthroughs for Hypertension Notification Feature (HTNF).

View all on YouTube

Frequently Asked Questions

The HTNF is designed to integrate with most major EHR systems, often utilizing standard APIs like FHIR, to embed notifications directly into physician dashboards or patient charts. This seamless data exchange aims to streamline clinical workflows by providing timely, actionable insights without significant disruption.
The HTNF adheres to strict HIPAA regulations through robust encryption, access controls, and de-identification protocols for patient data, and a Business Associate Agreement (BAA) is required with third-party vendors. Depending on its classification, it may have FDA clearance as a Software as a Medical Device (SaMD), which involves rigorous review for safety and efficacy.
While generally accurate, the HTNF's performance can be influenced by the quality and completeness of data within the EHR, and potential algorithmic biases from training data. Physicians should use notifications as supplementary information, exercising independent clinical judgment and considering all patient-specific factors, as AI is a support tool and not a replacement for human expertise.
The HTNF differentiates itself by leveraging advanced AI for proactive identification of at-risk patients and potential trends, moving beyond static alerts or manual review. While other tools exist for remote monitoring or basic flagging, HTNF aims for predictive analytics and personalized insights to improve diagnosis, risk stratification, and management.
Pricing for healthcare AI solutions like HTNF often follows subscription-based models, which can be tiered based on factors like the number of active patients or integrated clinicians. Hybrid models combining a base fee with variable components (e.g., per patient or per test) are also common, aiming to balance predictability with usage.
Physicians must be aware of potential algorithmic biases that could perpetuate health disparities if the AI is trained on unrepresentative data. It is crucial to avoid over-reliance on AI, maintaining human oversight and critical thinking to prevent automation bias and ensure patient autonomy and equitable care.

Related Tools

EchoMD AutoEF
Caption Health (formerly Bay Labs, now part of GE HealthCare)
Cardiology AI
EchoMD AutoEF is an FDA-cleared AI software that automates the selection of echocardiogram clips and calculates left ventricular ejection fraction (EF), enhancing efficiency and accuracy in cardiac assessments.
ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm
Anumana, Inc.
Cardiology AI
An AI algorithm for screening cardiac amyloidosis using standard 12-lead ECGs.
DEEPVESSEL Plaque
Keya Medical Technology Co., Ltd.
Cardiology AI
An AI software platform for coronary plaque analysis and quantification from CT angiography.
WatchMate Software
Anumana, Inc.
Cardiology AI
Anumana is an AI-driven health technology company from nference, developing and delivering ECG algorithms enabling early diagnosis and intervention.
syngo.CT Coronary Cockpit
Siemens Healthineers
Cardiology AI
syngo.CT Coronary Cockpit is an AI-powered software tool by Siemens Healthineers for efficient and accurate CT coronary angiography analysis.
HeartLung AI-CVD®
HeartLung Corporation
Cardiology AI
HeartLung AI-CVD® is an FDA-cleared AI-powered quantitative imaging tool that provides automated CT-derived measurements for assessing cardiovascular and multisystem risks opportunistically.

See all Cardiology AI tools →

More from Apple

Atrial Fibrillation History Feature
Apple
Cardiology AI
Apple's AFib History Feature on Apple Watch provides diagnosed users with retrospective estimates of AFib burden and insights into how lifestyle factors may influence their condition, with data exportable for physician review.
IRNF App
Apple
Cardiology AI
The Apple Irregular Rhythm Notification Feature (IRNF) is an FDA-cleared software-only mobile medical application for Apple Watch and iPhone that detects irregular heart rhythms suggestive of Atrial Fibrillation (AFib) and notifies users.
Irregular Rhythm Notification Feature (IRNF)
Apple
Cardiology AI
Apple's FDA-cleared Irregular Rhythm Notification Feature (IRNF) for Apple Watch screens for irregular heart rhythms suggestive of AFib, empowering users with notifications to facilitate discussions with their physicians.
Sleep Apnea Notification Feature (SANF)
Apple
Clinical Decision Support & Reference
Apple's Sleep Apnea Notification Feature (SANF) on Apple Watch uses AI to detect patterns of breathing disturbances suggestive of moderate to severe sleep apnea in undiagnosed adults, providing notifications and a shareable PDF report for physician discussion. It received FDA 510(k) clearance as an over-the-counter software-only mobile medical application.

View company profile →

Suggest an Edit → | Last Verified: 2026-04-17 | First Added: 2026-04-17

Investors who backed Hypertension Notification Feature (HTNF)

Funded through the company that built this tool.

AI Tool Finder
AI-powered search. Results may not be comprehensive.